PROGENICS PHARMACEUTICALS INC
DelistedCIK 835887fmd_1EKQTFZACEFWEPB1Q29F4EF369Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2020, 41 periods
Latest annual · FY2019
Millions- Total revenues
- 35
- Gross profit
- 32
- Operating income
- (66)
- Net income
- (69)
- Free cash flow
- (82)
Latest quarter · Q1 FY2020
Millions- Total revenues
- 6
- Gross profit
- 5
- Operating income
- (16)
- Net income
- (17)
- Free cash flow
- (11)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- -20.4%
- Revenue, 5 yearsFY2014 to FY2019
- -4.6%
- Net income, 5 yearsFY2014 to FY2019
- n/m
PROGENICS PHARMACEUTICALS INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $35 million | $15.6 million | +124% | 10-K 2020-03-13 · proof |
| Gross profit | $31.8 million | 10-K 2020-03-13 · proof | ||
| Operating income | -$66.2 million | -$66.4 million | 10-K 2020-03-13 · proof | |
| Net income | -$68.6 million | -$67.7 million | 10-K 2020-03-13 · proof | |
| Cash from operating activities | -$74.7 million | -$46.8 million | 10-K 2020-03-13 · proof | |
| Free cash flow | -$81.9 million | -$47.6 million | 10-K 2020-03-13 · proof | |
| Total assets | $119.5 million | $169.5 million | -29.5% | 10-K 2020-03-13 · proof |
| Total liabilities | $72.9 million | $68.4 million | +6.6% | 10-K 2020-03-13 · proof |
| Cash and cash equivalents | $42 million | $137.7 million | -69.5% | 10-K 2020-03-13 · proof |
| Total debt | $39 million | $44.6 million | -12.5% | 10-K 2020-03-13 · proof |
- What was PROGENICS PHARMACEUTICALS INC's revenue in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported revenue of $35 million for fiscal 2019 (the year ended Dec 31, 2019), against $15.6 million the year before (+124%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was PROGENICS PHARMACEUTICALS INC's gross profit in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported gross profit of $31.8 million for fiscal 2019 (the year ended Dec 31, 2019). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was PROGENICS PHARMACEUTICALS INC's operating income in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported operating income of -$66.2 million for fiscal 2019 (the year ended Dec 31, 2019), against -$66.4 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was PROGENICS PHARMACEUTICALS INC's net income in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported net income of -$68.6 million for fiscal 2019 (the year ended Dec 31, 2019), against -$67.7 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was PROGENICS PHARMACEUTICALS INC's cash from operating activities in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported cash from operating activities of -$74.7 million for fiscal 2019 (the year ended Dec 31, 2019), against -$46.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What was PROGENICS PHARMACEUTICALS INC's free cash flow in fiscal 2019?
- PROGENICS PHARMACEUTICALS INC reported free cash flow of -$81.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$47.6 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are PROGENICS PHARMACEUTICALS INC's total assets?
- As of Dec 31, 2019, PROGENICS PHARMACEUTICALS INC reported total assets of $119.5 million, against $169.5 million a year earlier (-29.5%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are PROGENICS PHARMACEUTICALS INC's total liabilities?
- As of Dec 31, 2019, PROGENICS PHARMACEUTICALS INC reported total liabilities of $72.9 million, against $68.4 million a year earlier (+6.6%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What are PROGENICS PHARMACEUTICALS INC's cash and cash equivalents?
- As of Dec 31, 2019, PROGENICS PHARMACEUTICALS INC reported cash and cash equivalents of $42 million, against $137.7 million a year earlier (-69.5%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
- What is PROGENICS PHARMACEUTICALS INC's total debt?
- As of Dec 31, 2019, PROGENICS PHARMACEUTICALS INC reported total debt of $39 million, against $44.6 million a year earlier (-12.5%). Source: the 10-K filed with the SEC on Mar 13, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:835887&period_type=annual&limit=5"Information only, not investment advice.